Posted in M&A / Deals Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug March 25, 2026 BioPharma Dive If consummated, the deal would hand Merck a treatment that could challenge Novartis fast-selling Scemblix. M&A / DealsHematologyRead full story